About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

NCT02164500·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Cologne

Age

18–99

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

relapsed or refractory HL
ECOG \<= 2,
no major organ dysfunction
written informed consent

You may not be if

history of another primary malignancy ≤ 2 years
female patients who are pregnant or breast feeding
patients with a known history of HIV seropositivity
chronic active hepatitis

The record

StatusCompleted

PhasePhase 2

Taking part12

StartedOct 2015

UpdatedApr 6, 2020

Conditions

Recurrent Classical Hodgkin Lymphoma

Where1

1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany

Clareo Health | JAK-inhibition in Recurrent Classical Hodgkin Lymphoma